Generation Bio's Q3 net loss narrows to $5.5 mln

Reuters

Nov 06

<a href="https://laohu8.com/S/GBIO">Generation Bio</a>'s Q3 net loss narrows to $5.5 mln

Overview

Generation Bio Q3 net loss improves to $5.5 mln from $15.3 mln last year
Company's collaboration revenue declines sharply in Q3
Lease settlement results in $25.5 mln gain on lease termination

Outlook

Company expects cash reserves to fund operations for foreseeable future

Result Drivers

LEASE SETTLEMENT - Co recorded a $25.5 mln gain from a lease termination settlement
INCREASED EXPENSES - R&D and G&A expenses rose due to ongoing investments
COLLABORATION REVENUE DECLINE - Co's collaboration revenue fell significantly in Q3

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$1.59 mln
Q3 EPS		-$0.82
Q3 Net Income		-$5.52 mln
Q3 Basic EPS		-$0.82
Q3 Operating Expenses		$8.30 mln
Q3 Operating Income		-$6.71 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 61.1% above its November 4 closing price of $5.25

Press Release: ID:nGNX2l50tv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581091707"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581091707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581091707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581091707","market":"fut","top_or_hot":-1,"title":"Generation Bio's Q3 net loss narrows to $5.5 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/GBIO\">Generation Bio</a>'s Q3 net loss narrows to $5.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Generation Bio Q3 net loss improves to $5.5 mln from $15.3 mln last year</p></li><li><p>Company's collaboration revenue declines sharply in Q3</p></li><li><p>Lease settlement results in $25.5 mln gain on lease termination</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations for foreseeable future</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LEASE SETTLEMENT - Co recorded a $25.5 mln gain from a lease termination settlement</p></li><li><p>INCREASED EXPENSES - R&amp;D and G&amp;A expenses rose due to ongoing investments</p></li><li><p>COLLABORATION REVENUE DECLINE - Co's collaboration revenue fell significantly in Q3</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$1.59 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.82</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$5.52 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.82</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$8.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$6.71 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 61.1% above its November 4 closing price of $5.25</p></li></ul><p>Press Release: <span>ID:nGNX2l50tv</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Generation Bio's Q3 net loss narrows to $5.5 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeneration Bio's Q3 net loss narrows to $5.5 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/GBIO\">Generation Bio</a>'s Q3 net loss narrows to $5.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Generation Bio Q3 net loss improves to $5.5 mln from $15.3 mln last year</p></li><li><p>Company's collaboration revenue declines sharply in Q3</p></li><li><p>Lease settlement results in $25.5 mln gain on lease termination</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations for foreseeable future</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LEASE SETTLEMENT - Co recorded a $25.5 mln gain from a lease termination settlement</p></li><li><p>INCREASED EXPENSES - R&amp;D and G&amp;A expenses rose due to ongoing investments</p></li><li><p>COLLABORATION REVENUE DECLINE - Co's collaboration revenue fell significantly in Q3</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$1.59 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.82</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$5.52 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.82</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$8.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$6.71 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 61.1% above its November 4 closing price of $5.25</p></li></ul><p>Press Release: <span>ID:nGNX2l50tv</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1EJ:1","article_id":"2581091707","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581091707","pubTimestamp":1762379049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Generation Bio's Q3 net loss narrows to $5.5 mlnOverviewGeneration Bio Q3 net loss improves to $5.5 mln from $15.3 mln last yearCompany's collaboration revenue declines sharply in Q3Lease settlement r","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4139":"生物科技","GBIO":"Generation Bio Co."},"translate_title":"Generation Bio第三季度净亏损收窄至550万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GBIO":0.9},"content_text":"Generation Bio's Q3 net loss narrows to $5.5 mlnOverviewGeneration Bio Q3 net loss improves to $5.5 mln from $15.3 mln last yearCompany's collaboration revenue declines sharply in Q3Lease settlement results in $25.5 mln gain on lease terminationOutlookCompany expects cash reserves to fund operations for foreseeable futureResult DriversLEASE SETTLEMENT - Co recorded a $25.5 mln gain from a lease termination settlementINCREASED EXPENSES - R&D and G&A expenses rose due to ongoing investmentsCOLLABORATION REVENUE DECLINE - Co's collaboration revenue fell significantly in Q3Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$1.59 mlnQ3 EPS-$0.82Q3 Net Income-$5.52 mlnQ3 Basic EPS-$0.82Q3 Operating Expenses$8.30 mlnQ3 Operating Income-$6.71 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 61.1% above its November 4 closing price of $5.25Press Release: ID:nGNX2l50tvFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}